|
|
|
| Changes of clinical test indexes after treatment with common psychotropic drugs |
| GUO Qi LING Sihai HE Jing LI Wenbiao LIU Chengeng▲ WANG Gang▲ |
| Department of Clinical Laboratory, Beijing Anding Hospital, Capital Medical University National Clinical Medical Research Center for Mental Disorders Beijing Key Laboratory of Diagnosis and Treatment of Mental Disorders Advanced Innovation Center for Human Brain Protection Capital Medical University, Beijing 100088, China |
|
|
|
Abstract In the treatment of psychotropic illness, the use of psychotropic drugs is particularly important. The International Convention on Psychotropic Substances fully affirms the medical and scientific value of psychotropic substances. While psychotropic drugs are effective, their toxic effects involve many aspects of the nervous system, and affect the heart, liver, kidney, and other important organs as well as blood and endocrine system functions, it can cause changes in relevant test indicators, including blood routine, coagulation function, liver and kidney function, blood glucose, blood lipid, blood electrolyte, myocardial injury markers, prolactin, and thyroid hormone, etc. The changes of blood test indexes can comprehensively reflect the pathophysiological changes experienced by the body, so as to evaluate the severity of the disease, judge the prognosis, guide treatment, and treatment monitoring.
|
|
|
|
|
|
[1] 王仙凤，张瑨.500例精神病患者服用抗精神病药物后致白细胞减少的回顾性分析[J].健康研究，2018，38（1）：76- 78.
[2] 丁仰，卢玟燊.抗精神分裂症药物致白细胞减少的调查分析[J].中国现代药物应用，2020，14（16）：230-231.
[3] Lahdelma L，Appelberg B. Clozapine-induced agranulocytosis in Finland，1982-2007：long-term monitoring of patients is still warranted [J]. J Clin Psychiatry，2012，73（6）：837- 842.
[4] Pons A，Undurraga J，Batalla A，et al. Clozapina y agranulocitosis en Espa?觡a：tenemos una población más segura? Seguimiento hematológico a 5 a?觡os de una cohorte de pacientes tratados con clozapina Clozapine and agranulocitosis in Spain：do we have a safer population? A 5-year hematologic follow-up [J]. Rev Psiquiatr Salud Ment，2012，5（1）：37-42.
[5] Midbari Y，Ebert T，Kosov I，et al. Hematological and cardiometabolic safety of clozapine in the treatment of very early onset schizophrenia：a retrospective chart review [J]. J Child Adolesc Psychopharmacol，2013，23（8）：516-521.
[6] Mattai A，Fung L，Bakalar J，et al. Adjunctive use of lithium carbonate for the management of neutropenia in clozapine-treated children [J]. Hum Psychopharmacol，2009，24（7）：584-589.
[7] Guenette MD，Powell V，Johnston K，et al. Risk of neutropenia in a clozapine-treated elderly population [J]. Schizophr Res，2013，148（1/3）：183-185.
[8] Legge SE，Hamshere ML，Ripke S，et al. Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia [J]. Mol Psychiatry，2017， 22（10）：1509.
[9] Saito T，Ikeda M，Mushiroda T，et al. Pharmacogenomic Study of Clozapine-Induced Agranulocytosis / Granulocytopenia in a Japanese Population [J]. Biol Psychiatry，2016，80（8）：636-642.
[10] 刘咏梅.精神病患者血常规参数的临床观察[J].检验医学与临床，2012，9（13）：1650-1651.
[11] 李艳.不同抗抑郁症药物对抑郁症患者凝血指标的影响[J].血栓与止血学，2022，28（3）：2.
[12] 张琦，夏丰，刘群，等.不同抗抑郁症药物对抑郁症患者凝血功能的影响[J].检验医学与临床，2020，17（8）：1101- 1104.
[13] Yamamoto T，Abe K，Kuyama Y. Selective serotonin reuptake inhibitor and gastrointestinal hemorrhage [J]. Nihon Rinsho，2013，71（4）：751-756.
[14] Ventriglio A，Gentile A，Stella E，et al. Metabolic issues in patients affected by schizophrenia：clinical characteristics and medical management [J]. Front Neurosci，2015，3（9）：297.
[15] Stahl SM. Stahl’s essential psychopharmacology：neuroscientific basis and practical applications [M]. Cambridge university press，2021.
[16] Grajales D，Ferreira V，Valverde ?譧M. Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism：Beyond Weight Gain [J]. Cells，2019，8（11）：1336.
[17] Ulcickas Yood M，DeLorenze GN，Quesenberry CP，et al. Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus：does the effect differ by dose?[J]. BMC psychiatry，2011，11（1）：1-6.
[18] 徐学文，吴向平，马宏，等.3种抗精神病药物对精神分裂症患者血糖指标、血脂指标的影响[J].中国现代医生，2021，59（11）：104-107.
[19] 吴小立，秦峰，王继辉，等.精神分裂症患者血脂代谢异常情况及停用抗精神病药物的影响[J].中华神经医学杂志，2015，14（2）：156-161.
[20] David T. Maudsley精神科处方指南[M].司天梅.北京：人民卫生出版社，2016：259-260.
[21] Brown S，Inskip H，Barraclough B. Causes of the excess mortality of schizophrenia [J]. Br J Psychiatry，2000，177：212-217.
[22] Melkersson KI，Hulting AL，Brismar KE. Elevated levels of insulin，leptin，and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses [J]. J Clin Psychiatry，2000，61（10）：742-749.
[23] Sheitman BB，Bird PM，Binz W，et al. Olanzapine-induced elevation of plasma triglyceride levels [J]. Am J Psychiatry，1999，156（9）：1471-1472.
[24] Henderson DC，Cagliero E，Gray C，et al. Clozapine，diabetes mellitus，weight gain，and lipid abnormalities：A five-year naturalistic study [J]. Am J Psychiatry，2000，157（6）：975-981.
[25] 侯成业，陈智敏，温乃义，等.3种非典型抗精神病药治疗精神分裂症对肝功能影响的对照研究[J].中国新药杂志，2015，24（8）：908-911.
[26] 毕玉萍，罗小年.常用抗精神病药物对肝功能影响的临床研究报道实录[J].中南药学，2013，11（2）：150-153.
[27] Chaplin AC，Curley MA，Wanless IR. Re：Recent case report of clozapine-induced acute hepatic failure [J]. Can J Gastroenterol，2010，24（12）：739-740.
[28] 胡卫红，徐韩，丁宇杰，等.非典型抗精神病药物对老年患者心脏功能的影响[J].神经疾病与精神卫生，2014， 14（3）：291-292.
[29] 张啸飞，胡大一，丁荣晶，等.中国心脑血管疾病死亡现况及流行趋势[J].中华心血管病杂志，2012，40（3）：179-187.
[30] Mazhar F，Battini V，Pozzi M，et al. Hyponatremia Following Antipsychotic Treatment：In Silico Pharmacodynamics Analysis of Spontaneous Reports From the US Food and Drug Administration Adverse Event Reporting System Database and an Updated Systematic Review [J]. Int J Neuropsychopharmacol，2021，24（6）：477-489.
[31] 黄晓，葛永纯，徐峰，等.碳酸锂治疗后肾病综合征[J].肾脏病与透析肾移植杂志，2017，26（6）：583-586.
[32] 李朝晖，赖小红，眭维国，等.锂中毒肾损害-附9例报道[J].国际泌尿系统杂志，2008，28（4）：437-440.
[33] Van Alphen AM，Bosch TM，Kupka RW，et al. Chronic kidney disease in lithium-treated patients，incidence and rate of decline [J]. Int J Bipolar Disord，2021，9（1）：1.
[34] Baddour E，Tewksbury A，Stauner N. Valproic acid-induced hyperammonemia：Incidence，clinical significance，and treatment management [J]. Ment Health Clin，2018，8（2）：73-77.
[35] Yeung G，Chau KW，Woo Y，et al. A fatal case of valproate-induced hyperammonemic encephalopathy：An update on proposed pathogenic mechanisms and treatment options [J]. Internat J Epilepsy，2017：181-183.
[36] Elwadhi D，Prakash R，Gupta M. The Menacing Side of Valproate：A Case Series of Valproate-induced Hyperammonemia [J]. Indian J Psychol Med，2017，39（5）：668-670.
[37] 崔海珍，王华.丙戊酸钠致高氨血症脑病和癫痫加重1例[J].中国药物应用与监测，2021，18（3）：204-206.
[38] 陈晶贞，朱仁敬，林晓芳，等.丙戊酸致高氨血症脑病二例并文献复习[J].实用药物与临床，2019，22（7）：730- 733.
[39] Kapur S，Seeman P. Does fast dissociation from the dopamine d（2） receptor explain the action of atypical antipsychotics：A new hypothesis [J]. Am J Psychiatry，2001，158（3）：360- 369.
[40] Mittal S，Prasad S，Ghosh A. Antipsychotic-induced hyperprolactinaemia：case studies and review [J]. Postgrad Med J，2018，94（1110）：226-229.
[41] Dar SA，Bhat BA，Khanam A，et al. Thyroid hormone levels and Thyroid Hormone Levels and Ultrasonographic Changes in the Thyroid Gland of Patients on Long-Term Lithium Treatment for Affective Disorders：A Controlled Study [J]. J Med Ultrasound，2020，28（2）：104-110.
[42] Zhang JX，Li X. Changes in serum thyroid hormone levels in psychiatric patients treated with second-generation antipsychotics [J]. Endokrynol Pol，2020，71（4）：292-298. |
|
|
|
